615 filings
Page 16 of 31
8-K
dpjkd
14 Jun 12
Submission of Matters to a Vote of Security Holders
12:00am
8-K
prtt 2pv9
8 May 12
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
12:00am
DEFA14A
dsf ftmd1dk11
26 Apr 12
Additional proxy soliciting materials
12:00am
8-K
v5v1bqe
26 Apr 12
Results of Operations and Financial Condition
12:00am
CT ORDER
2kg6i6afqama3in57
12 Apr 12
Confidential treatment order
12:00am
8-K
ddkf54c6jmteqkr
13 Feb 12
Regeneron Reports Fourth Quarter and Full Year 2011 Financial and Operating Results
12:00am
8-K/A
2tfvfn6a02g2lmuszcq
24 Jan 12
Departure of Directors or Certain Officers
12:00am
8-K
fmrmt 77s
10 Jan 12
Regulation FD Disclosure
12:00am
8-K
cb24rv8ok vvshn
3 Jan 12
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
12:00am
8-K
28r770ndwumb 1g6
21 Dec 11
Regulation FD Disclosure
12:00am
8-K
01mmb1tg
5 Dec 11
Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity
12:00am
8-K
k1klj883xwx c18
22 Nov 11
Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
12:00am
8-K/A
8qpwvmvtv7y
22 Nov 11
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
12:00am
8-K
mj973gv4 le285ry7l
21 Nov 11
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
12:00am
8-K
3fejdz
14 Nov 11
Regulation FD Disclosure
12:00am
8-K
7mz fmh4pyuq7d26c5
3 Nov 11
Regulation FD Disclosure
12:00am